Physiomics PLC Contract award
23 Dicembre 2019 - 8:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
23 December 2019
23 December 2019
Physiomics plc
("Physiomics") or (the "Company")
Contract award
Physiomics signs further project agreement with CellCentric
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens for the biopharma industry, is delighted to announce that
it has been awarded a further contract by existing UK based biotech
client, CellCentric. The value of the contract is not disclosed but
is expected to complete in the first half of 2020.
The project will involve pharmacokinetic and pharmacodynamic
modelling and build on the work completed over the course of 2019
in support of the clinical development of CellCentric's lead asset
CCS1477. This is a first in class small molecule inhibitor of
p300/CBP, currently in Phase 1/2 trials for the treatment of late
stage, drug-resistant prostate cancer as well as haematological
malignancies.
A summary of some of the work that the Company has previously
completed with CellCentric is available as a case study on the
Physiomics website and can be accessed using the following
hyperlink:
https://www.physiomics.co.uk/wp-content/uploads/2019/03/CC-case-study.pdf.
Dr Jim Millen, CEO said:
"We are looking forward to continuing to work with CellCentric,
one of the UK's most exciting young biotech companies."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 20 3764 2341
Notes to Editor
About Physiomics
Physiomics(R) is an oncology consultancy which uses mathematical
PKPD models as well as its proprietary Virtual Tumour(TM)
technology to predict the effects of cancer drugs and treatments
and improve the success rate of drug discovery and development
projects. The predictive capability of Virtual Tumour has been
confirmed by 55 projects, involving over 25 targets and 60 drugs,
and has worked with clients such as Merck KGaA, Merck & Co,
Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
For more information please visit:
www.physiomics-plc.com
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGGCUPUPBGQU
(END) Dow Jones Newswires
December 23, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Physiomics (LSE:PYC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Physiomics (LSE:PYC)
Storico
Da Apr 2023 a Apr 2024